Related references
Note: Only part of the references are listed.Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC)
Luis Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Toxicities of Immunotherapy for the Practitioner
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi et al.
LANCET ONCOLOGY (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay et al.
SEMINARS IN CANCER BIOLOGY (2015)
Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma
Edward J. Gettings et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma
Yan Feng et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease
Magnus Pedersen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Ipilimumab in patients with melanoma and autoimmune disease
Chrisann Kyi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
Salvatore Maria Corsello et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Meghna Das Thakur et al.
NATURE (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Ipilimumab and Its Toxicities: A Multidisciplinary Approach
Leslie A. Fecher et al.
ONCOLOGIST (2013)
Therapy for metastatic melanoma: the past, present, and future
Laura Finn et al.
BMC MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis
Christine E. Eyler et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cancer-related inflammation
Alberto Mantovani et al.
NATURE (2008)
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
Kimberly E. Beck et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study
AV Maker et al.
ANNALS OF SURGICAL ONCOLOGY (2005)
Monoclonal antibodies as therapeutic agents for cancer
M Harris
LANCET ONCOLOGY (2004)
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
FV Fossella et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
